Benitec restates Q2 and Q3 FY2025 financials for stock-comp understatement; prior filings unreliable

Benitec Biopharma Inc.

Audit Committee concluded Dec 31, 2024 and Mar 31, 2025 unaudited financials should no longer be relied upon.
Error from November 2023 system migration incorrectly configured equity awards data, understating share-based compensation.
Non-cash adjustments understated additional paid-in capital, accumulated deficit, net loss, and loss per share.
Restated financials to be included in FY2025 Form 10-K, expected to be filed on or before the deadline.

item 4.02

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.